copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Microsoft Word - Egrifta SV BLA 022505 S-018 final PI The recommendations in this prescribing information only apply to EGRIFTA SV (tesamorelin) for injection 2 mg per vial formulation For recommendations for tesamorelin for injection 1 mg per vial formulation, see the EGRIFTA prescribing information
HIGHLIGHTS OF PRESCRIBING INFORMATION EGRIFTA SV for injection is supplied in a single-dose 2 mg vial as a white to off-white lyophilized powder and a diluent of 10 mL of Sterile Water for Injection, USP
EGRIFTA WR For complete disclosure of EGRIFTA WR TM product information, please read the Full Prescribing Information, Patient Information, and Patient Instructions for Use
label - accessdata. fda. gov This Patient Information leaflet summarizes the most important information about EGRIFTA® If you would like more information, talk with your healthcare provider
Dosing Administration - EGRIFTA SV The impact and safety of EGRIFTA SV ® on cardiovascular health have not been studied EGRIFTA SV ® is not indicated for weight loss management It is not known whether taking EGRIFTA SV ® helps improve compliance with anti‑retroviral medications
Resources for You and Your Patients - hcp. egriftawr. com Learn about the EGRIFTA WR TM mechanism of action, key data, dosing and administration, and more Provide patients with information about EGRIFTA WR TM and why it could be an option for them Help patients have informed conversations with their doctor about EVAF and EGRIFTA WR TM therapy
label - accessdata. fda. gov For recommendations for tesamorelin for injection 2 mg per vial formulation, see the EGRIFTA SV prescribing information These two formulations and strengths have differences in the dosage,